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Abstract Autism is a neurodevelopmental disorder of
complex genetics, characterized by impairment in social
interaction and communication, as well as repetitive
behavior. Multiple lines of evidence, including alterations
in levels of GABA and GABA receptors in autistic
patients, indicate that the GABAergic system, which is
responsible for synaptic inhibition in the adult brain, may
be involved in autism. Previous studies in our lab indicated
association of noncoding single nucleotide polymorphisms
(SNPs) within a GABA receptor subunit gene on chromo-
some 4, GABRA4, and interaction between SNPs in
GABRA4 and GABRB1 (also on chromosome 4), within
Caucasian autism patients. Studies of genetic variation in
African-American autism families are rare. Analysis of 557
Caucasian and an independent population of 54 African-
American families with 35 SNPs within GABRB1 and
GABRA4 strengthened the evidence for involvement of
GABRA4 in autism risk in Caucasians (rs17599165,
p=0.0015; rs1912960, p=0.0073; and rs17599416,
p=0.0040) and gave evidence of significant association in
African-Americans (rs2280073, p=0.0287 and rs168
59788, p=0.0253). The GABRA4 and GABRB1 interaction
was also confirmed in the Caucasian dataset (most
significant pair, rs1912960 and rs2351299; p=0.004).
Analysis of the subset of families with a positive history
of seizure activity in at least one autism patient revealed no
association to GABRA4; however, three SNPs within
GABRB1 showed significant allelic association; rs2351
299 (p=0.0163), rs4482737 (p=0.0339), and rs3832300
(p=0.0253). These results confirmed our earlier findings,
indicating GABRA4 and GABRB1 as genes contributing to
autism susceptibility, extending the effect to multiple
ethnic groups and suggesting seizures as a stratifying
phenotype.
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Introduction
Autism is a neurodevelopmental disorder characterized by
severe impairment in social interaction and communication,
as well as repetitive behavior. Autism is part of a spectrum
of disorders denoted autism spectrum disorders (ASD),
which in addition to autism, include Asperger syndrome,
childhood disintegrative disorder, and pervasive develop-
mental disorder not otherwise specified (PDD-NOS). Onset
of this disorder is typically before 3 years of age. The
incidence of autism is estimated at approximately one in
1,000 individuals, with an increased incidence in males
[1–3]. Incidences of approximately two to three in 1,000 are
reported when a broader diagnosis includes the entire
spectrum of pervasive developmental disorders [2, 4].
Evidence indicates that this disease has a strong genetic
component. Twin studies have shown that monozygote
twins have a higher recurrence rate than dizygotic twins.
While the actual percentages have varied, recurrence rates
have been measured as high as 95% in monozygote twins
and 23% in dizygotic twins [5–7]. Despite this strong
evidence for a genetic component, the inheritance appears
to be complex, with estimates that more than 15 genes may
be involved in its inheritance [8, 9], with different families
carrying different combinations of contributing genes. The
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There are two approaches to identifying genetic
contributors to disease. The first is a genome wide search
in which linkage or association analysis is used to identify
regions of the genome that may contain autism suscepti-
bility genes. The second is the candidate gene approach,
which investigates a specific gene orgenes for involvement
in autism risk. In the candidate gene approach, genes are
chosen for study based on either what is known about the
gene’s function, its location (for example in a recognized
linkage peak), or a combination of both. Several candidates
are hypothesized to be involved in autism; however, no
single candidate gene has consistently emerged as involved
in autism risk.
One candidate pathway that is hypothesized to be
involved in autism is the GABAergic system. Hussman
[10] suggested that autism is the result of an imbalance of
the excitatory glutamatergic and inhibitory GABAergic
pathways, resulting in overstimulation in the brain and
inability to filter out excess stimuli from environmental and
intrinsic sources. This theory is supported by multiple lines
of evidence. First, histological, biochemical, and molecular
approaches have demonstrated altered levels and distribu-
tion of GABA and GABA receptors in peripheral blood
and plasma, as well as in the brain, including decreased
GABA-A receptors and benzodiazepine binding sites in the
hippocampal formation [11–13]. There are also reported
alterations in GABAergic neurons, as demonstrated by the
increased packing density of GABAergic interneurons in
the CA3 and CA1 subfields, and by the decreased numbers
and reduced size of cerebellar GABAergic Purkinje cells
[14, 15]. In addition, duplications and isodicentric chromo-
somes in the region containing the three clustered GABA
receptor subunits GABRB3, GABRA5, and GABRG3 on
chromosome 15q have been associated with autism
[16, 17]. As well, evidence for both linkage and allelic
association have been reported for this same GABA gene
cluster, although the findings have not been consistent
across datasets [18–22]. Investigation of association of
GABA receptor subunits outside of the chromosome 15
region has been limited [23]. Lastly, mutations have been
reported in multiple GABA receptor genes in families with
epilepsy [24]. Given the high comorbidity of autism with
epilepsy and seizures, these data suggest that a similar
molecular etiology could exist between the disorders.
Signaling in the GABAergic system is mediated by
receptors for the neurotransmitter GABA. There are 19
known GABA receptor subunits arranged in clusters
throughout the genome. Functional pentamers formed by
various combinations of these subunits result in receptors
of varying properties and sensitivities. The amounts and
functional capabilities of individual receptor subunits that
form a specific pentamer can affect the amount and quality
of signaling in different parts of the brain.
Previously published work from our laboratory analyzed
14 autosomal GABA receptor genes on four different
chromosomes, using 70 SNPs in a Caucasian dataset of 470
families. This analysis revealed allelic association to
rs1912960 (p=0.01) within gamma-aminobutyric acid
(GABA) A receptor, alpha-4 (GABRA4) on chromosome
4[ 23] and a significant interaction with rs2351299 within
the neighboring gene gamma-aminobutyric acid (GABA)
A receptor, beta-1 (GABRB1).
Despite similar prevalence rates between Caucasian and
African-Americans [25, 26], autism studies in African-
Americans are rare. Risk alleles may be different between
ethnic groups or the same risk alleles may have differential
effects in each ethnic group, warranting studies in multiple
groups. Evidence that phenotypic factors, including indica-
tors of language development, may be more severe in
African-Americans, compared to non-Hispanic Caucasians,
[27]isconsistentwiththesepossibilitiesandunderscoresthe
need to investigate autism in different ethnic groups. In this
study, we present a validation of our previous report in an
independent dataset of 54 African-American families, as
well as confirmation of our previous results in an expanded
Caucasian sample of 557 autism families.
Materials and methods
Samples
All families were drawn from a large multisite study of
autism genetics conducted in the southeastern United
States. These families are recruited through the Center for
Human Genetics (CHG) at Duke University Medical
Center (DUMC), the University of South Carolina, and
the Center for Human Genetic Research at Vanderbilt
(N=54 African-American and 557 Non-Hispanic Cauca-
sian families) through support groups, advertisements, and
clinical and educational settings. All sites recruited,
enrolled, and sampled individuals with autism and family
members, per study protocols approved by their respective
institutional review boards (IRBs). Written informed
consent was obtained from parents and from children
who were able to give informed consent. Families were
enrolled based on probands meeting the following core
inclusion criteria of: (1) probands ranging from three to
21 years of age; (2) a presumptive clinical diagnosis of
autism; and (3) an expert clinical diagnosis of autism using
DSM-IV criteria [28], supported by the Autism Diagnostic
Interview-Revised (ADI-R) [29] and in some cases, the
Autism Diagnostic Observation Schedule (ADOS) [30].
Our original ascertainment protocol relied on clinical
expertise and the ADI-R. The ADOS was subsequently
added as a required diagnostic method, and families that
were missing ADOS assessments were updated as avail-
able. To assure valid ADI-R results, all participants who
met current diagnostic criteria for autism were included
only if they had a minimal developmental level of
18 months, as extrapolated from the Vineland Adaptive
Behavior Scale score [31], or had an IQ equivalent greater
than 35 based on scores from a standardized measure of
cognitive ability such as an the Wechsler Scale of
Intelligence for Children—4th edition [32], Differential
168Abilities Scale [33],Mullen Scalesof Early Learning[34]o r
Leiter Intelligence Scale-Revised [35]. IQ data was derived
from medical records or direct assessment. Exclusion
criteria for participation in the larger genetics study
included: severe sensory problems (e.g., visual impairment
or hearing loss), significant motor impairments (e.g., failure
to sit by 12 months, or walk by 24 months), or identified
metabolic, genetic, or progressive neurological disorders,
based on screening by clinical staff. Additional samples are
from the Autism Genetic Research Exchange (AGRE).
These individuals were qualified using similar methods
including ADI-R, ADOS, VABS, and a standardized
measure of IQ.
Thirty-nine African-American families were used in an
initial GABA receptor screen. Follow-up analysis of
significant findings was performed in 54 African-American
families. Analysis of the extended Caucasian dataset
included 557 non-Hispanic Caucasian families. One-
hundred and five new non-Hispanic Caucasian families
were added to the analysis (18 families previously analyzed
by Ma et al. [23] were newly identified as Hispanic, and
were omitted from the current study in an effort decrease
heterogeneity in the Caucasian dataset).
Classification of history of seizure activity in autism
patients was based on question 92 from the ADI-R, which
queries for both current and lifetime presence of convul-
sions, seizures, and epilepsy. Caregiver responses to
question 92 are coded to indicate no seizure activity,
seizure activity with no definitive diagnosis of epilepsy,
and seizures with a definite diagnosis of epilepsy. Using
lifetime ratings, two groups of families were defined: those
in which no seizure activity was reported, and those in
which seizure activity was present in at least one autism
patient. In addition, question 92 allows for coding offebrile
seizures. Families with only febrile seizures were classified
as negative for seizure activity and not included in the
seizure subset analysis. Both families with positive and
negative history of seizure activity were included in our
overall dataset. This resulted in a dataset of 41 Caucasian
families with a positive history for seizures.
Molecular analyses and genotyping
The analysis of 14 GABA receptor subunit genes was
performed in 39 African-American families as previously
described [23]. Briefly, between three and seven intronic,
UTR and synonymous coding SNPs within each gene were
identified from Applied Biosystems (ABI, Foster City, CA,
USA) Assay on Demand (AoD) products, resulting in 70
SNPs within 14 GABA receptor genes on four autosomes.
Genes analyzed were: GABRA1, GABRA6, GABRB2,
GABRG2, and GABRP from chromosome 5; GABRA2,
GABRA4, GABRB1, and GABRG1 from chromosome 4;
GABRB3, GABRA5, and GABRG3 from chromosome 15;
and GABRR1 and GABRR2 from chromosome 6.
Additional SNPs within GABRA4 and GABRB1 were
analyzed in the extended African-American (N=54) and
Caucasian (N=557) datasets to expand the coverage of
variation across this region. Thirty-five SNPs, representa-
tive of different linkage disequilibrium (LD) blocks across
the two genes (20 in GABRA4 and 15 in GABRB1), were
genotyped (Fig. 1). SNP’s for genotyping were selected
from online databases (University of California Santa Cruz
http://genome.ucsc.edu and NCBI dbSNP http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp) and from re-
sequencing of exons and surrounding areas of both
GABRB1 and GABRA4 genes.
SNP genotyping was performed using Taqman allelic
discrimination assays (Applied Biosystems). DNA was
extracted from whole blood according to established
protocols [36], and 3 ng of genomic DNA was used per
reaction. Amplification was performed on GeneAmp PCR
Systems 9700 thermocyclers, with cycling conditions as
recommended by Applied Biosystems. Fluorescence was
measured using Applied Biosystem’s 7900. Genotype
discrimination was conducted using ABI Prism SDS 2.1
software. Quality control, to ensure accurate genotyping,
involved two different CEPH DNAs in quadruplicate on
each 384 well plate, as well as the presence of samples
which were replicated elsewhere in the sample list.
Additionally, ≥95% genotyping efficiency is required.
Fig. 1 Approximate locations of SNPs for extended analysis within
GABRA4 and GABRB1. Horizontal arrows represent transcriptional
direction. Vertical arrows represent SNPs, as numbered and
identified below the diagram. Pter indicates the P-terminal end of
the chromosome and cen indicates the centromere
169Statistical analysis
To ensure genotyping quality, Pedcheck was run for
detection of Mendelian inheritance inconsistency. One
affected and one unaffected individual from each family
were selected randomly for tests of Hardy–Weinberg
equilibrium (HWE), which was assessed using exact tests
from the Genetic Data Analysis program [37]. Pairwise LD
between markers was calculated using graphical overview
of linkage disequilibrium (GOLD) [38] in the parents of
autism cases for both the African-American and Caucasian
samples. LD was evaluated in parents to increase the
available sample size for analysis and comparison between
the two ethnic groups. The pedigree disequilibrium test
(PDT) and its extension the genotypic pedigree disequilib-
rium test (genoPDT) [39, 40]w e r eu s e dt ot e s tf o r
association to autism susceptibility.
The EMDR [23, 41], an extension of the MDR [42, 43],
was used to test for potential gene–gene interaction, to
identify specific locus combinations of interest for further
investigation and validation of previous results. EMDR
analysis was performed using seven SNPs, the four in
GABRA4 found to show significant allelic or genotypic
association in the Caucasian sample-set, and the three in
GABRB1 found to be significant in the seizure subgroup.
One-, two-, and three-way analysis was performed on the
Caucasian dataset. For case-control pairs used in EMDR,
the proband (or most completely genotyped affected child)
from each multiplex and triad family was selected (n=470
total) as a case. Controls were generated using the
untransmitted alleles from parental genotypes. In this
study, a cross-validation option was not utilized. The
sample size of the African-American dataset is too small to
provide power for EMDR analysis, not allowing us to test
for validation of the interaction seen in the paper of Ma
et al. within the African-American dataset.
The haplotype family-based association test (HBAT;
[44]) was used for haplotype association analysis using the
significant SNPs in GABRA4.
Results
Allelic association studies of 70 SNPs across the 14 GABA
receptor subunit genes in the 39 African-American screen
set of families, revealed association in rs2280073
(GABRA4; p=0.0053) and hcv2119841 (GABRB1;
p=0.0343), the same two genes identified through allelic
association and interaction analysis in the Caucasian
dataset [23]. Genotypic association analysis revealed the
same GABRA4 SNP, rs2280073 (p=0.0262), and marginal
significance within GABRP, rs1862242 (p=0.0471). The
remaining SNPs showed no significant association (data
not shown).
Analysis of the screening SNPs and newly identified
SNPs within GABRA4 and GABRB1 in the Caucasian
population (N=557), and within the extended African-
American population (N=54) (Table 1), revealed new SNPs
Table 1 Analysis of GABRA4 and GABRB1 in extended Caucasian and African-American datasets
GABRA4 GABRB1
SNP Caucasian African-American SNP Caucasian African-American
PDT
a Geno PDT
a PDT
a Geno PDT
a PDT Geno PDT PDT Geno PDT
RS7678338 0.9350 0.9923 0.2230 0.4190 RS1866989 0.3071 0.3860 0.5553 0.7892
RS6447517 0.8826 0.7034 0.505 0.3930 RS2351299 0.4529 0.0822 0.5775 0.8614
RS17599102 0.8055 0.8913 0.7518 0.8805 RS10016388 0.1585 0.2660 0.2367 0.4259
RS7660336 0.0833 0.0368(G/G) 0.5164 0.7410 RS1372496 0.2362 0.3740 0.2482 0.3715
RS1512136 0.9052 0.9869 0.2888 0.3575 RS3114084 0.0934 0.1942 0.2059 0.3281
RS17599165 0.0015(T) 0.0009(T/T) 0.6547 0.4304 RS4482737 0.1495 0.2504 1.0000 1.0000
HCV1592545 0.7798 0.9427 0.2230 0.5313 HCV11353524 0.1959 0.3117 1.0000 1.0000
RS7685553 1.0000 0.8419 0.4913 0.6044 RS3775534 0.1893 0.1831 0.4913 0.4913
RS1912960 0.0073(C) 0.0046(C/C) 0.4111 0.5110 HCV2119841 0.3352 0.0838 0.2278 0.4111
RS2055943 0.9671 0.9434 0.4927 0.7607 RS6287 0.4045 0.3571 0.6171 0.6984
RS2280073 0.1404 0.0955 0.0287(G) 0.1100 RS6289 0.9349 0.5554 0.8658 0.9220
RS16859788 0.3173 0.3173 0.0253(A) 0.0412(A/A) RS6290 0.4285 0.1973 0.3173 0.4594
RS17599416 0.0040(A) 0.0043(A/A) 0.8084 0.8084 4P0413 1.0000 1.0000 0.7389 0.7389
RS3792208 1.0000 0.4980 0.1797 0.1797 RS10028945 0.3272 0.4584 1.0000 0.8179
RS10517174 0.9484 0.0894 0.7150 0.8903 RS3832300 0.4094 0.6352 0.6547 0.6547
RS7694035 0.4337 0.6266 0.3657 0.3657
RS3792211 0.9057 0.8382 0.6547 0.2895
RS2229940 0.7873 0.9375 0.5485 0.7866
RS13151759 0.7529 0.9326 0.2367 0.5759
RS13151769 0.4740 0.7436 0.1824 0.4768
Bold indicates significant values
aAssociated allele/genotype shown in parenthesis
170with significant association. In the Caucasian dataset,
rs1912960, also significant in the study of Ma et al.
(p=0.012), showed significant allelic association
(p=0.0073). Additional significant SNPs were identified
in GABRA4 as well, rs17599165 (p=0.0015) and rs1759
9416 (p=0.0040). Genotypic association was also seen in
these SNPs (p=0.0046, 0.0009, and 0.0043, respectively),
as well as in a fourth SNP, also in GABRA4 (rs7660336,
p=0.0368). In the African-American dataset, rs2280073
(p=0.0287), identified in the smaller African-American
dataset above, and rs16859788 (p=0.0253), were found to
be associated with the allele based test. Genotypic asso-
ciation was also identified in rs16859788 (p=0.0412). No
SNPs within GABRB1 were found to be associated with
autism in either ethnic group.
The majority of pairwise r
2 values between the signif-
icant SNPs were less than 0.3, in both ethnic groups
(Table 2). However, a few SNPs have values between 0.3
and 0.35. SNPs, rs17599165, and rs17599416 have r
2
values of 0.709 in African-Americans and 0.853 in
Caucasians, and rs7660336 and rs2280073 have a pairwise
r
2 of 0.907 in Caucasians and 0.905 in African-Americans.
Allele frequencies are similar, yet not identical between the
two groups. One SNP, however, did have large differences
in minor allele frequencies (MAFs) between the two
groups, with a MAF of 0.24 in African-Americans but only
0.001 in Caucasians (Table 2). Haplotype analysis, using
the four SNPs with significant allelic or genotypic
association in the Caucasian families, revealed a significant
global test (p=0.014) in the Caucasian population, further
supporting the involvement of these SNPs or another
variant on the haplotype background. The haplotype
composed of all risk alleles trends towards significance
with autism as a risk haplotype (p=0.0763), while the
haplotype of all protective alleles resulted in being highly
significantly protective (p=0.0006; Table 3)
Subsetting of the GABRA4 and GABRB1 data to analyze
all families with positive history for seizures revealed no
association to GABRA4. However, three SNPs within
GABRB1 were found to be both allelically and genotypi-
cally associated with autism: rs2351299 (p=0.0163 and
p=0.0189 for PDT and genoPDT, respectively), rs4482737
(p=0.0339 and p=0.0339), and rs3832300 (p=0.0253 and
p=0.0357). These three SNPs all had pairwise r
2 values less
than 0.1 (data not shown).
In the Caucasian population, EMDR verified the single
locus effect identified through PDT analysis in rs1912960
(p=0.024), and identified two different significant two-
locus gene–gene effects between GABRA4 and GABRB1,
rs1912960 with rs2351299 (p=0.004), and rs17599416
with rs2351299 (p=0.014). Several three locus effects
were also significant [rs7660336, rs1912960, and rs2351
299 (p=0.012); rs17599165, rs1912960, and rs2351
299 (p=0.012); rs1912960, rs17599416, and rs2351299
(p=0.038); and rs7660336, rs17599416, and rs2351299
(p=0.047)] (Table 4).
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Table 2 Minor allele frequencies and linkage disequilibrium in Caucasian and African-American datasets
Bold indicates significant values
aMAF minor allele frequency
Table 3 Haplotype frequency and association in Caucasian population
RS7660336 RS17599165 RS1912960 RS17599416 Haplotype frequency P-value
G T C A 0.503 0.0763
C T C A 0.277 0.9214
C T G A 0.124 0.6094
C A G G 0.082 0.0006
Bold indicates significant values
171Discussion
We have confirmed the involvement of GABRA4 in autism
through identification of significantly associated SNPs
within an independent African-American population.
Furthermore, we have strengthened our original findings,
including identification of additional associated SNPs and
a significant interaction between GABRA4 and GABRB1
and in an extended dataset (N=557) of Caucasian autism
families. The AA dataset contains only 54 families, and in
general power can be a problem in small sample sets if an
effect is not seen. However, for the GABRA4 gene, we did
find significant results in the AA dataset. Furthermore,
studies in small datasets such as the AA dataset can also be
less robust than in larger datasets. However, the fact that we
find the same gene, GABRA4, significant in two different
ethnic groups is supportive of the role of GABRA4 in
autism risk.
The identification of two different two-way interactions
between GABRA4 and GABRB1 provides additional
evidence of the complex interaction of these two genes in
autism. The rs1912960 (GABRA4) with rs2351299
(GABRB1) interaction is between the same two SNPs
previously reported in the study of Ma et al., and is still
significant in our larger dataset. A second significant two-
way interaction was found, also including rs2351299 in
GABRB1 as well as rs17599416 in GABRA4, further
supporting that interactions between these two genes are
involved in autism risk. Although rs2351299 does not have
a significant PDT result, it is found in both significant
interaction pairs, and in each of the significant three-way
interactions. The MDR approach used in these analyses is
specifically designed to detect interaction effects both in
the presence and absence of main effects.
It is possible that both of the two-way interactions are
being identified due to LD between the two GABRA4 SNPs
(rs1912960 and rs17599416). There is significant correla-
tion between the two SNPs, although the r
2 value (Table 2)
between them is not large (0.32). Given that these do not
appear to be causative variants, it is likely that the true
variant, yet to be identified, is in LD with these GABRA4
SNPs. Examination of interaction in the independent dataset
of African-American families was not possible due to the
limited sample size.
We also identified variants within GABRB1 as associated
within the autistic population with seizures. One of these
variants, rs2351299, also shows a significant interaction
with SNPs in GABRA4 (Table 4). While no effect was seen
in GABRA4 for the seizure subset, the sample size may be
too small to conclusively determine its role in seizure status
in autism. However, the enhanced findings in GABRB1 in
the seizure subset implicate GABRB1 as a contributor to
genetic risk in these patients.
Despite the identification of GABRA4 in both ethnic
groups, different SNPs were found to be associated. The
identification of distinct SNPs within these populations may
indicate differences in allele frequency and linkage disequi-
librium within the two racial groups, differences in the
haplotypic background in which identical causative varia-
tions originated, or differences in the causative variation.
SNP rs16859788 for example, which is significant in the
African-American group, shows little variation in the Cau-
casian dataset, therefore, providing no power for detection
of an effect in this group. Other SNPs, however, show
similar allele frequencies between the two populations.
Some differences in LD do exist between the two ethnic
groups as well; however, the majority of the differences are
small. The largest differences in LD are in pairwise values
with rs16859788, which appear to mostly be due to the fact
that the SNP is practically monoallelic in the Caucasian
population. The Caucasian dataset suggests that there is a
significant association of SNP haplotypes with autism risk,
while the African-American set does not. However, this
difference may be due to the small size of the African-
American dataset. Therefore, while it appears that minor
allele frequency differences can account for the lack of
association of rs16859788 in the Caucasian dataset,
additional studies are needed to determine whether the
other differences in results between the two ethnic groups
are due to sample size differences, differential LD with the
causative variation in the two populations, or are popula-
tion-specific risk alleles.
Whilewe have identified several associated SNPs, wedo
not predict any of the ones in GABRA4 to have functional
consequences; therefore, it is unlikely that these are
primary variants leading to the autism susceptibility. One
of the SNPs identified in GABRB1 in the seizure subset,
however, is in the 3′ untranslated region (UTR). Given that
multiple GABA receptor subunits combine in varying
combinations to form a functional GABA receptor, even
minor changes in levels of a particular subunit may alter the
makeup of receptors within a particular cell type, and alter
Table 4 EMDR results in Caucasian dataset between GABRA4 and GABRB1
Input SNPs Significant interactions
Gene SNP number SNP SNPs P-values
GABRA4 1 RS7660336 One-way 3 0.024
2 RS17599165 Two-way 3, 5 0.004
3 RS1912960 4, 5 0.014
4 RS17599416 Three-way 1, 3, 5 0.012
GABRB1 5 RS2351299 2, 3, 5 0.012
6 RS4482737 3, 4, 5 0.038
7 RS3832300 1, 4, 5 0.047
172the GABAergic signaling. Therefore, variations within
potential regulatory regions, such as untranslated regions
and promoters, could play an important role. It will be
important to look at potential changes that may result from
this and other potential GABRB1 UTR variations, as well as
sequence coding and potential regulatory regions to
identify the primary variation, or variations leading to
altered autism susceptibility.
In summary, these data show that the GABA receptors
are implicated in the etiology of autism in two different
ethnic populations and suggest seizures as a stratifying
phenotype. Furthermore, these results support our earlier
findings, indicating GABRA4 and GABRB1 as genes
contributing to autism susceptibility, independently, in the
case of GABRA4, and through complex interactions with
each other.
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